U.S. Markets closed
  • S&P 500

    4,297.14
    +16.99 (+0.40%)
     
  • Dow 30

    33,912.44
    +151.39 (+0.45%)
     
  • Nasdaq

    13,128.05
    +80.87 (+0.62%)
     
  • Russell 2000

    2,021.35
    +4.73 (+0.23%)
     
  • Crude Oil

    88.33
    -1.08 (-1.21%)
     
  • Gold

    1,794.80
    -3.30 (-0.18%)
     
  • Silver

    20.20
    -0.07 (-0.33%)
     
  • EUR/USD

    1.0167
    -0.0091 (-0.8845%)
     
  • 10-Yr Bond

    2.7910
    -0.0580 (-2.04%)
     
  • Vix

    19.95
    +0.42 (+2.15%)
     
  • GBP/USD

    1.2056
    -0.0083 (-0.6800%)
     
  • USD/JPY

    133.1270
    -0.3530 (-0.2645%)
     
  • BTC-USD

    24,103.13
    -228.69 (-0.94%)
     
  • CMC Crypto 200

    571.41
    -19.35 (-3.28%)
     
  • FTSE 100

    7,509.15
    +8.26 (+0.11%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Lumos Pharma, Inc.
Lumos Pharma, Inc.

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks.

Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (833) 634-2295 (U.S.) or +1 (412) 902-4176 (international), or through the link, https://edge.media-server.com/mmc/p/ofen9o6f. The link to the live webcast may also be found in the “Investors & Media” section of the Lumos Pharma website, under “Events & Presentations.” A replay of the call will be available for two weeks from the date of the call and may be accessed through the same link above or by dialing (877) 344-7529 (U.S.) or +1 (412) 317-0088 (international) and using the passcode: 1602592.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.


Source: Lumos Pharma, Inc.

CONTACT: Investor & Media Contact: Lisa Miller Lumos Pharma Investor Relations 512-792-5454 ir@lumos-pharma.com